Get started
Author

Heike Schönherr

Observed names: Heike Schoenherr, Heike Schonherr
Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Columbia University Irving Medical Center, Relay Therapeutics (United States), AstraZeneca (United States), Columbia University, Leipzig University
ORCID: 0009-0005-0269-8646
Observed ORCID: 0009-0005-0269-8646
OpenAlex ID: A5081078298
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
2013 · Heike Schönherr, Tim Cernak · Angewandte Chemie International Edition · 1,113
Ausgeprägte Methyleffekte in der Wirkstoff‐Forschung und der Bedarf an neuen C‐H‐Methylierungsreaktionen
2013 · Heike Schönherr, Tim Cernak · Angewandte Chemie · 175
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2023 · Vivek Subbiah, Vaibhav Sahai, et al. · Cancer Discovery · 132
PDF
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
2024 · Heike Schönherr, Pelin Ayaz, et al. · Proceedings of the National Academy of Sciences · 82
PDF
An improved model for fragment-based lead generation at AstraZeneca
2016 · Nathan Fuller, Loredana Spadola, et al. · Drug Discovery Today · 80
Direct and Highly Enantioselective Iso-Pictet–Spengler Reactions with α-Ketoamides: Access to Underexplored Indole Core Structures
2012 · Heike Schönherr, James L. Leighton · Organic Letters · 65
ChemInform Abstract: Profound Methyl Effects in Drug Discovery and a Call for New C—H Methylation Reactions
2014 · Heike Schoenherr, Tim Cernak · ChemInform · 55
Fragment-based Differential Targeting of PPI Stabilizer Interfaces
2020 · Xavier Guillory, Madita Wolter, et al. · Journal of Medicinal Chemistry · 49
Synthesis of Antioxidants for Prevention of Age-Related Macular Degeneration
2013 · Dharati Joshi, James Field, et al. · Journal of Natural Products · 37
Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations
2021 · Jessica Casaletto, Dejan Maglic, et al. · Cancer Research · 17
A Chemoenzymatic Approach to the Stereocontrolled Synthesis of the C1–C11 fragment of (+)‐Peloruside A
2010 · Heike Schönherr, Jan Mollitor, et al. · European Journal of Organic Chemistry · 13
ChemInform Abstract: Direct and Highly Enantioselective Iso‐Pictet—Spengler Reactions with α‐Ketoamides: Access to Underexplored Indole Core Structures.
2012 · Heike Schoenherr, James L. Leighton · ChemInform · 2
Data from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2023 · Vivek Subbiah, Vaibhav Sahai, et al. · 1
Cryptic small-molecule binding sites in the ARID1B DNA-binding domain
2026 · Christine E. Carbone, Heike Schönherr, et al. · Proceedings of the National Academy of Sciences
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Works count: 118
Citation count: 1,821
H-index: 11
I10-index: 11
Year
Topic
Type